IL17A and inflammatory bowel disease: This will increase the expression of pro-inflammatory factors, such as TNF-α, IFN–γ, and IL-17, and reduce the expression of anti-inflammatory factors, such as IL-10, which will eventually induce local inflammatory response and cause or aggravate IBD.